ClinPharm Consulting is offering new services to enable biopharmaceutical companies to reduce drug development risks and maximize return on R&D investment.
The services are derived from insights into preventable issues revealed by the firm’s clinical pharmacology and PK-PD work across numerous client projects.
“Our new services arise from important concepts that our clients are seeking, including sound strategic and scientific advice and rapid delivery of services at an affordable cost,” said ClinPharm Consulting’s Chief Scientific Officer, Bill Wargin, PhD, adding, “We’re developing proactive solutions to help avoid development delays for companies and maximize their return on R&D investment.”
The new services offered by ClinPharm Consulting include the following:
In addition to these new services, ClinPharm Consulting is seeing growing interest in customized clinical pharmacology plans to address important issues and prevent delays in clinical studies, providing a road map to clients’ programs and identifying key areas to avoid risk.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.